Improving the in silico assessment of proarrhythmia risk by combining hERG (Human Ether-à-go-go-Related Gene) channel-drug binding kinetics and multichannel pharmacology

Zhihua Li, Sara Dutta, Jiansong Sheng, Phu N. Tran, Wendy Wu, Kelly Chang, Thembi Mdluli, David G. Strauss, Thomas Colatsky

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

Background - The current proarrhythmia safety testing paradigm, although highly efficient in preventing new torsadogenic drugs from entering the market, has important limitations that can restrict the development and use of valuable new therapeutics. The CiPA (Comprehensive in vitro Proarrhythmia Assay) proposes to overcome these limitations by evaluating drug effects on multiple cardiac ion channels in vitro and using these data in a predictive in silico model of the adult human ventricular myocyte. A set of drugs with known clinical torsade de pointes risk was selected to develop and calibrate the in silico model. Methods and Results - Manual patch-clamp data assessing drug effects on expressed cardiac ion channels were integrated into the O'Hara-Rudy myocyte model modified to include dynamic drug-hERG channel (human Ether-à-go-go-Related Gene) interactions. Together with multichannel pharmacology data, this model predicts that compounds with high torsadogenic risk are more likely to be trapped within the hERG channel and show stronger reverse use dependency of action potential prolongation. Furthermore, drug-induced changes in the amount of electronic charge carried by the late sodium and L-type calcium currents was evaluated as a potential metric for assigning torsadogenic risk. Conclusions - Modeling dynamic drug-hERG channel interactions and multi-ion channel pharmacology improves the prediction of torsadogenic risk. With further development, these methods have the potential to improve the regulatory assessment of drug safety models under the CiPA paradigm.

Original languageEnglish (US)
Article numbere004628
JournalCirculation: Arrhythmia and Electrophysiology
Volume10
Issue number2
DOIs
StatePublished - Feb 1 2017
Externally publishedYes

Fingerprint

Computer Simulation
Ether
Pharmacokinetics
Pharmacology
Pharmaceutical Preparations
Genes
Ion Channels
Muscle Cells
Safety
Torsades de Pointes
Drug Design
Action Potentials
Sodium
Calcium
In Vitro Techniques

Keywords

  • biomarkers
  • ion channels
  • torsade de pointes

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)

Cite this

Improving the in silico assessment of proarrhythmia risk by combining hERG (Human Ether-à-go-go-Related Gene) channel-drug binding kinetics and multichannel pharmacology. / Li, Zhihua; Dutta, Sara; Sheng, Jiansong; Tran, Phu N.; Wu, Wendy; Chang, Kelly; Mdluli, Thembi; Strauss, David G.; Colatsky, Thomas.

In: Circulation: Arrhythmia and Electrophysiology, Vol. 10, No. 2, e004628, 01.02.2017.

Research output: Contribution to journalArticle

Li, Zhihua ; Dutta, Sara ; Sheng, Jiansong ; Tran, Phu N. ; Wu, Wendy ; Chang, Kelly ; Mdluli, Thembi ; Strauss, David G. ; Colatsky, Thomas. / Improving the in silico assessment of proarrhythmia risk by combining hERG (Human Ether-à-go-go-Related Gene) channel-drug binding kinetics and multichannel pharmacology. In: Circulation: Arrhythmia and Electrophysiology. 2017 ; Vol. 10, No. 2.
@article{db9c2e01f66346b093ebe280a42816ae,
title = "Improving the in silico assessment of proarrhythmia risk by combining hERG (Human Ether-{\`a}-go-go-Related Gene) channel-drug binding kinetics and multichannel pharmacology",
abstract = "Background - The current proarrhythmia safety testing paradigm, although highly efficient in preventing new torsadogenic drugs from entering the market, has important limitations that can restrict the development and use of valuable new therapeutics. The CiPA (Comprehensive in vitro Proarrhythmia Assay) proposes to overcome these limitations by evaluating drug effects on multiple cardiac ion channels in vitro and using these data in a predictive in silico model of the adult human ventricular myocyte. A set of drugs with known clinical torsade de pointes risk was selected to develop and calibrate the in silico model. Methods and Results - Manual patch-clamp data assessing drug effects on expressed cardiac ion channels were integrated into the O'Hara-Rudy myocyte model modified to include dynamic drug-hERG channel (human Ether-{\`a}-go-go-Related Gene) interactions. Together with multichannel pharmacology data, this model predicts that compounds with high torsadogenic risk are more likely to be trapped within the hERG channel and show stronger reverse use dependency of action potential prolongation. Furthermore, drug-induced changes in the amount of electronic charge carried by the late sodium and L-type calcium currents was evaluated as a potential metric for assigning torsadogenic risk. Conclusions - Modeling dynamic drug-hERG channel interactions and multi-ion channel pharmacology improves the prediction of torsadogenic risk. With further development, these methods have the potential to improve the regulatory assessment of drug safety models under the CiPA paradigm.",
keywords = "biomarkers, ion channels, torsade de pointes",
author = "Zhihua Li and Sara Dutta and Jiansong Sheng and Tran, {Phu N.} and Wendy Wu and Kelly Chang and Thembi Mdluli and Strauss, {David G.} and Thomas Colatsky",
year = "2017",
month = "2",
day = "1",
doi = "10.1161/CIRCEP.116.004628",
language = "English (US)",
volume = "10",
journal = "Circulation: Arrhythmia and Electrophysiology",
issn = "1941-3149",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Improving the in silico assessment of proarrhythmia risk by combining hERG (Human Ether-à-go-go-Related Gene) channel-drug binding kinetics and multichannel pharmacology

AU - Li, Zhihua

AU - Dutta, Sara

AU - Sheng, Jiansong

AU - Tran, Phu N.

AU - Wu, Wendy

AU - Chang, Kelly

AU - Mdluli, Thembi

AU - Strauss, David G.

AU - Colatsky, Thomas

PY - 2017/2/1

Y1 - 2017/2/1

N2 - Background - The current proarrhythmia safety testing paradigm, although highly efficient in preventing new torsadogenic drugs from entering the market, has important limitations that can restrict the development and use of valuable new therapeutics. The CiPA (Comprehensive in vitro Proarrhythmia Assay) proposes to overcome these limitations by evaluating drug effects on multiple cardiac ion channels in vitro and using these data in a predictive in silico model of the adult human ventricular myocyte. A set of drugs with known clinical torsade de pointes risk was selected to develop and calibrate the in silico model. Methods and Results - Manual patch-clamp data assessing drug effects on expressed cardiac ion channels were integrated into the O'Hara-Rudy myocyte model modified to include dynamic drug-hERG channel (human Ether-à-go-go-Related Gene) interactions. Together with multichannel pharmacology data, this model predicts that compounds with high torsadogenic risk are more likely to be trapped within the hERG channel and show stronger reverse use dependency of action potential prolongation. Furthermore, drug-induced changes in the amount of electronic charge carried by the late sodium and L-type calcium currents was evaluated as a potential metric for assigning torsadogenic risk. Conclusions - Modeling dynamic drug-hERG channel interactions and multi-ion channel pharmacology improves the prediction of torsadogenic risk. With further development, these methods have the potential to improve the regulatory assessment of drug safety models under the CiPA paradigm.

AB - Background - The current proarrhythmia safety testing paradigm, although highly efficient in preventing new torsadogenic drugs from entering the market, has important limitations that can restrict the development and use of valuable new therapeutics. The CiPA (Comprehensive in vitro Proarrhythmia Assay) proposes to overcome these limitations by evaluating drug effects on multiple cardiac ion channels in vitro and using these data in a predictive in silico model of the adult human ventricular myocyte. A set of drugs with known clinical torsade de pointes risk was selected to develop and calibrate the in silico model. Methods and Results - Manual patch-clamp data assessing drug effects on expressed cardiac ion channels were integrated into the O'Hara-Rudy myocyte model modified to include dynamic drug-hERG channel (human Ether-à-go-go-Related Gene) interactions. Together with multichannel pharmacology data, this model predicts that compounds with high torsadogenic risk are more likely to be trapped within the hERG channel and show stronger reverse use dependency of action potential prolongation. Furthermore, drug-induced changes in the amount of electronic charge carried by the late sodium and L-type calcium currents was evaluated as a potential metric for assigning torsadogenic risk. Conclusions - Modeling dynamic drug-hERG channel interactions and multi-ion channel pharmacology improves the prediction of torsadogenic risk. With further development, these methods have the potential to improve the regulatory assessment of drug safety models under the CiPA paradigm.

KW - biomarkers

KW - ion channels

KW - torsade de pointes

UR - http://www.scopus.com/inward/record.url?scp=85013413533&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85013413533&partnerID=8YFLogxK

U2 - 10.1161/CIRCEP.116.004628

DO - 10.1161/CIRCEP.116.004628

M3 - Article

VL - 10

JO - Circulation: Arrhythmia and Electrophysiology

JF - Circulation: Arrhythmia and Electrophysiology

SN - 1941-3149

IS - 2

M1 - e004628

ER -